Close Menu

influenza

The firm sells a rapid, point-of-care, PCR platform for infectious disease diagnostics, including SARS-CoV-2, influenza, respiratory syncytial virus, and Strep A.

The company, which is developing instrument-free, low-cost molecular diagnostics platform for infectious disease testing, plans to float its shares on the Nasdaq.

The kit was jointly developed by Singapore's Agency for Science, Technology, and Research, Tan Tock Seng Hospital, and MiRxes.

The company is also working in parallel on an at-home test that would be over the counter and return results within an hour.

The PCR-based panel is designed to simultaneously detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus, with results in less than two hours.

Genetworx and PacificDx's tests detect SARS-CoV-2 nucleic acid, while Hologic's test can also detect and differentiate SARS-CoV-2 and influenza A and B.

The panel simultaneously tests for SARS-CoV-2 and influenza viruses A and B, while a second analysis detects for human respiratory syncytial virus and human metapneumovirus.

The firm is developing a test to determine interleukin-6 levels for SARS-CoV-2 patients and a rapid antigen test.

The test kit, which provides results in under two hours, is PCR system-agnostic and is suitable for use with a range of instruments, according to the company.

The PCR test detects SARS-CoV-2, influenza A/B, and respiratory syncytial virus type A and B and runs on the Elite InGenius platform and other major thermcyclers.

Pages